In PNAS this week: germline variants influence tumor immune gene expression in two dozen cancer types, phylogenetic relationships of hemipteroid insects, and more.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.
Based on the results of the SANDPIPER study in advanced, PIK3CA-mutated breast cancer, Genentech has decided not to advance development of the PI3 kinase inhibitor taselisib.
A new study finds that a shorter treatment course might work just as well as a longer one for women with early-stage HER2-positive breast cancer, NPR says.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.
